Related by context. All words. (Click for frequent words.) 73 oxycodone CR 72 achieved ACR# 72 desvenlafaxine succinate 71 tapentadol ER 71 statistically significant p = 70 noninferiority 70 tolterodine ER 70 morphometric vertebral fractures 70 CIMZIA TM 69 mcg QD 69 CIMZIA ™ 69 lumbar spine BMD 69 statistically significant p 69 ADCS CGIC 69 placebo p = 69 mg TID 69 abacavir lamivudine 69 ritonavir boosted 69 placebo p 68 attain statistical significance 68 mcg BID 68 certolizumab 68 mg QD 68 active comparator 68 4mg/kg 68 pharmacokinetic parameters 68 #mg BID [001] 68 prospectively defined 67 comparator arm 67 lopinavir r 67 oral rivaroxaban 67 venlafaxine XR 67 prespecified 67 plus methotrexate 67 tirofiban 67 demonstrated statistically significant 67 #.#/#.# mmHg [001] 67 Primary endpoints 67 insulin detemir 67 ULORIC 67 HBeAg seroconversion 67 salmeterol fluticasone 67 8mg/kg 67 baseline HbA1c 67 methotrexate monotherapy 67 maximally tolerated dose 67 HBeAg negative patients 67 #mg doses [002] 67 TEAEs 67 fluticasone salmeterol 67 lipid parameters 67 mg BID dose 67 MoxDuo TM IR 67 nicardipine 67 ALVESCO 67 ATACAND 66 LEXIVA r 66 mg ustekinumab 66 lispro 66 apolipoprotein B 66 irbesartan 66 ACTEMRA TM 66 intravenous dosing 66 oral diclofenac 66 secondary efficacy endpoints 66 ARB telmisartan 66 teriflunomide 66 Secondary endpoints included 66 somatostatin analog 66 μg kg 66 timolol 66 peginterferon alfa 2b 66 eplerenone 66 ADAS Cog 66 octreotide LAR 66 atazanavir ritonavir 66 Pred Forte 66 primary efficacy endpoints 66 achieved PASI 66 APTIVUS r 66 headache nasopharyngitis 66 secondary efficacy endpoint 66 μg dose 66 LPV r 66 CANCIDAS 66 #mg BID [003] 66 noninferior 66 P = .# 66 non inferiority 66 piperacillin tazobactam 66 eszopiclone 66 Xalatan R 66 #mg/day [001] 66 dose proportionality 66 3mg/kg 66 CC genotype 66 antipsychotic efficacy 66 idraparinux 66 NPH insulin 65 mg p = 65 serum urate 65 clinically meaningful improvement 65 limiting toxicity 65 Montgomery Åsberg Depression 65 HbA 1c 65 mg dose 65 clomipramine 65 mesalamine granules 65 corticosteroid dose 65 p = .# [002] 65 pegylated liposomal doxorubicin 65 clodronate 65 MADRS score 65 Lucentis monotherapy 65 Doxil ® 65 ibandronate 65 administered subcutaneously 65 lopinavir r arm 65 tacrolimus ointment 65 prednisone prednisolone plus 65 solifenacin 65 cisplatin vinorelbine 65 apremilast 65 abciximab 65 #.#mg/dL 65 ruboxistaurin 65 interferon alfa 2b 65 CI -#.# 65 glargine 65 HOMA IR 65 PREZISTA r 65 dapagliflozin plus 65 ziprasidone 65 sUA 65 complete cytogenetic response 65 mcg kg 65 biphasic insulin aspart 65 statistical significance p 65 posaconazole 65 prospectively stratified 65 baminercept 65 Pegasys ® 65 PEGylated anti 65 HbA1c levels 65 achieve statistical significance 65 chlorambucil 65 XIENCE V demonstrated 65 RLAI 65 pyridostigmine 65 iniparib 65 mg kg dose 65 Engerix B 65 tipranavir r 65 dosage regimens 65 analgesic efficacy 64 FOLFOX4 64 cilostazol 64 titrated glipizide 64 dalteparin 64 bosentan 64 saline placebo 64 rotigotine 64 transdermal estradiol 64 μmol L 64 alanine aminotransferase ALT 64 FOLFIRI 64 atorvastatin #mg 64 ug kg 64 tapentadol IR 64 CIMZIA TM certolizumab pegol 64 haematologic 64 adjunctive placebo 64 % Confidence Interval 64 timepoint 64 febuxostat 64 relapsed MM 64 chlorthalidone 64 tenofovir emtricitabine 64 serum phosphorus 64 genotypic resistance 64 prespecified secondary 64 YMRS 64 pharmacodynamic properties 64 FOLPI 64 transaminase elevations 64 mg BID 64 paliperidone ER 64 DLTs 64 Rating Scale MADRS 64 nadroparin 64 Durezol 64 Cmax 64 ARCOXIA 64 candesartan cilexetil 64 ADAS cog 64 mL/min/#.# m 2 64 Neuropsychiatric Inventory NPI 64 intermittent dosing 64 paricalcitol 64 Secondary efficacy endpoints 64 mg/m2 dose 64 Secondary endpoints 64 receiving golimumab 64 tamsulosin 64 ACR# response 64 AEGR 64 QTcF 64 primary efficacy endpoint 64 glycated hemoglobin levels 64 clevidipine 64 #mg/day [002] 64 Pharmacokinetic studies 64 guanfacine extended release 64 alanine aminotransferase 64 confidence interval #.#-#.# 64 PASI scores 64 Crohn Disease Activity 64 darunavir ritonavir 64 salmeterol fluticasone propionate 64 5-FU/LV 64 FOLFOX6 64 intima media thickness 64 Viread Emtriva 64 #μg [002] 64 budesonide pMDI 64 -#.# mg dL [001] 64 bezafibrate 64 subcutaneously administered 64 avosentan 64 mg/# hours 64 β blockers 64 evaluating tivozanib 64 plus COPEGUS 64 HbA 1c levels 64 Montgomery Asberg Depression 64 plus prednisone prednisolone 64 TDF FTC 64 elevated ALT 64 selective modulator 64 Flu Cy 64 -#.# mg dL [002] 64 QD dosing 63 KRAS mutations occur 63 #mg QD [001] 63 methacholine challenge 63 XIENCE V PROMUS Stent 63 tolvaptan 63 pegaptanib 63 VAPRISOL 63 galiximab 63 epoetin alpha 63 binary restenosis 63 urinary N telopeptide 63 lymphopenia 63 leukocyte count 63 STRIDE PD 63 nonrandomized 63 elevated transaminases 63 splenectomized 63 neurologic progression 63 undetectable HBV DNA 63 certolizumab pegol 63 trospium 63 hsCRP levels 63 AUC0 63 infliximab monotherapy 63 urate lowering therapy 63 glulisine 63 COPEGUS 63 plasma pharmacokinetics 63 rosuvastatin #mg 63 elotuzumab 63 Index CDAI 63 placebo 63 FDA defined valvulopathy 63 HbA1C levels 63 INCB# [003] 63 secondary endpoint 63 plus MTX 63 tarenflurbil 63 P ≤ 63 demonstrated clinically meaningful 63 sitaxsentan 63 virologic response 63 composite endpoint 63 6R BH4 63 HCV RESPOND 2 63 colesevelam HCl 63 abdominal pain abdominal discomfort 63 DAS# CRP 63 Q2W 63 progression TTP 63 AUA Symptom Score 63 GOUT 63 ertapenem 63 Peg IFN 63 postintervention 63 ACR# ACR# 63 pharmacokinetic equivalence 63 aspirin clopidogrel 63 mg doses 63 primary endpoint 63 esomeprazole 63 definite stent thrombosis 63 clinically meaningful differences 63 statistically significant superiority 63 GSK# [001] 63 PEG IFN 63 zolmitriptan 63 BENICAR HCT 63 TNF Tumor Necrosis Factor 63 mg qd 63 hemoglobin A1c HbA1c 63 #ug [001] 63 Tarceva TM 63 interferon gamma 1b 63 clinically meaningful reductions 63 serum urate levels 63 subcutaneous insulin 63 seropositive patients 63 Subgroup analysis 63 HIV RNA 63 zoledronate 63 tiotropium bromide 63 efficacy endpoint 63 mg simvastatin 63 HDRS 63 mcg albinterferon alfa 2b 63 canakinumab 63 pharmacokinetic PK 63 locoregional recurrence 63 % CI #.#-#.# [003] 63 SGRQ 63 fosamprenavir 63 prucalopride 63 secondary endpoints 63 corrected QT interval 63 primary hypercholesterolemia 63 QTc 63 estramustine 63 plus dexamethasone 63 CR nPR 63 squamous histology 63 elagolix 63 TPV r 63 OADs 63 1mg dose 63 ug dose 63 placebo controlled clinical 63 pharmacokinetics PK 63 pentoxifylline 63 RoACTEMRA 63 log# copies mL 63 myopathy rhabdomyolysis 63 pramipexole 63 CsA 63 endometrial thickness 63 aplindore 63 annualized relapse 63 caspofungin 63 odanacatib 62 ciclesonide 62 fasting plasma glucose 62 Pharmacokinetic parameters 62 rolofylline 62 lamotrigine 62 inhaled iloprost 62 mmol l 62 rilpivirine 62 quetiapine XR 62 peginterferon alfa 2a 62 IFN α 62 dosing cohort 62 carboplatin paclitaxel 62 colorectal adenoma 62 EURIDIS 62 ritonavir boosted atazanavir 62 unresectable HCC 62 mg tid 62 serum cortisol 62 doxorubicin docetaxel 62 sargramostim 62 QTc prolongation 62 adjunctive ABILIFY 62 timepoints 62 antiarrhythmic 62 symptomatic VTE 62 hyperphenylalaninemia HPA due 62 cariprazine 62 PANSS 62 sirolimus stent 62 mcg mL 62 intact parathyroid hormone 62 microbiological eradication 62 INVEGA ® 62 reach statistical significance 62 sumatriptan naproxen sodium 62 amprenavir 62 Secondary endpoints include 62 fosbretabulin 62 aspartate aminotransferase 62 #mg dosing 62 tipranavir ritonavir 62 nasal symptom 62 HAM D# 62 thromboembolic events 62 Pharmacokinetics PK 62 postdose 62 oral antidiabetic medication 62 pharmacodynamic PD 62 #.#g/day 62 GERD symptom 62 -#.# log# 62 lanthanum carbonate 62 hematological parameters 62 Ceplene/IL-2 62 tocilizumab 62 recurrent glioblastoma multiforme 62 daily subcutaneous injections 62 SVR# 62 #mg QD [002] 62 CCyR 62 tolerability profiles 62 safinamide 62 #mg dose [002] 62 sirolimus eluting stent 62 mitoxantrone 62 placebo fluoxetine 62 alfuzosin 62 x ULN 62 1mg 2mg 62 melphalan prednisone 62 zonisamide SR 62 oxycodone IR 62 risedronate 62 liver histology 62 Ereska 62 REMINYL ® 62 glycoprotein IIb IIIa inhibitor 62 valacyclovir 62 tiotropium 62 KRN# 62 insulin degludec 62 IFN beta 62 serum retinol 62 nonsignificant 62 LT NS# 62 etanercept 62 angiographic outcomes 62 clinically meaningful 62 rapid virologic response 62 mg kg Hematide 62 adalimumab 62 MGd 62 tipranavir 62 CorVue ™ 62 PRADAXA #mg 62 laboratory abnormalities 62 micafungin 62 endoscopic remission 62 mycophenolate mofetil 62 CR CRu 62 F FDG PET 62 triamcinolone 62 demonstrated antitumor activity 62 tranylcypromine 62 azilsartan medoxomil 62 spontaneous bowel movements 62 metformin sulfonylurea 62 rizatriptan 62 GAMMAGARD 62 latanoprost 62 bicifadine 62 statistically significant 62 TLUS 62 Folfox 62 plasma leptin 62 pharmacodynamics PD 62 linaclotide treated 62 plus prednisone 62 interobserver reliability 62 postmenopausal osteoporotic women 62 atheroma volume 62 balsalazide 62 NATRECOR ® 62 Hazard Ratio = 62 ZOLINZA 62 trough FEV1 62 mcg doses 62 antiretroviral naïve 62 FFNS 62 Kinoid 62 SCIg 62 sorafenib Nexavar 62 Brief Psychiatric 62 nephrotoxicity 62 ancrod 62 nondiabetic patients 62 ribavirin USP 62 Navelbine 62 diabetic neuropathic pain 62 pCR 62 Non inferiority 62 clinically meaningful improvements 62 pain palliation 62 IOP lowering 62 ispinesib administered 62 Negative Syndrome 62 incidence ≥ 62 MoxDuo IR 62 pegylated interferon alfa 2b 62 ascending doses 62 log# IU mL 62 pruritus itching 62 doxorubicin cyclophosphamide 62 posttreatment 62 alicaforsen enema 62 benazepril 62 dacarbazine chemotherapy 62 maximal tolerated 62 mg subcutaneously 62 p = #.# [003] 62 dose cohort 62 #mg ritonavir 62 lenalidomide dexamethasone 62 weekly subcutaneous injections 62 sirolimus eluting stents 62 pharmacodynamic 62 ACR# responses 62 mcg dose 62 racemic albuterol 62 bupropion SR 62 creatinine ratio 62 trandolapril 62 subcutaneous enoxaparin 62 events AEs 62 #mg dose [003] 62 pharmacokinetic PK profile 62 HAQ DI 62 retinal vein occlusion 62 favorable pharmacokinetic profile 62 -#.# log# copies mL 62 5 HT2A 62 dose regimens 62 ascending dose 62 HBeAg positive patients 62 Severity MSCS score 62 metabolic parameters 62 steroid dexamethasone 62 plasma folate 61 nab paclitaxel 61 Psoriasis Area 61 lopinavir ritonavir 61 receptor inhibitor 61 alteplase 61 5 Fluorouracil 61 Elitek 61 ACEI ARB 61 PANSS scores 61 VELCADE melphalan 61 bovine thrombin 61 oxcarbazepine 61 fasting plasma glucose FPG 61 adenosine injection 61 serum concentrations 61 PROMACTA 61 pharmacokinetic profiles 61 p = NS 61 carotid IMT 61 mg XP# 61 HMG CoA reductase inhibitors 61 diameter stenosis 61 glycated hemoglobin HbA1c 61 glycosylated hemoglobin HbA1c 61 plasma renin activity 61 Alzheimer Disease Assessment 61 oral FTY# 61 sustained virologic response 61 nadolol 61 ketorolac 61 NEVO ™ 61 CK # plasma concentrations 61 lactate dehydrogenase LDH 61 rilonacept 61 SSRI citalopram 61 pharmacokinetic characteristics 61 Thal Dex 61 NATRECOR R 61 indinavir 61 NIH CPSI 61 biochemical relapse 61 carotid intima media 61 achieving PASI 61 serum phosphorous 61 edifoligide 61 HER2 expression 61 hip BMD 61 moderate renal impairment 61 serum HBV DNA 61 DOXIL 61 cobicistat 61 baseline A1C 61 nonresponders 61 Subgroup analyzes 61 primary endpoints 61 non splenectomized 61 infusional 61 valsartan 61 #-#,# mg 61 olanzapine LAI 61 seroprotection 61 Fulvestrant 61 montelukast 61 TIMP 1 61 ropivacaine 61 alvimopan 61 CRp 61 oblimersen 61 GW# [003] 61 RAPAFLO R 61 hydroxymethyl coenzyme 61 segment binary restenosis 61 olmesartan 61 RE LY ® 61 dose limiting toxicities 61 pharmacodynamic effects 61 oral levofloxacin 61 EDARBI 61 overt nephropathy 61 leukopenia 61 iloprost 61 serum PTH 61 bosutinib 61 treatment emergent AEs 61 glimepiride 61 ceftazidime 61 lipid lowering agents 61 TAXUS p value 61 #mg/m# [001] 61 serum phosphate 61 biologic DMARD 61 symptom severity 61 pramlintide metreleptin combination 61 albumin excretion rate 61 pamidronate 61 statistically significant efficacy 61 bronchial hyperresponsiveness 61 IV DHE 61 Visual Analogue Scale VAS 61 MAGE A3 ASCI 61 GLP1 agonist 61 antiarrhythmic drug 61 lixisenatide 61 tumor progression TTP 61 coadministration 61 raltegravir 61 viral kinetics 61 primidone 61 hemodynamically significant 61 APOPTONE 61 inflammatory lesions 61 Celsentri Selzentry 61 EDEMA3 61 flutamide 61 discontinuations due 61 ximelagatran 61 creatinine clearance 61 Kaplan Meier analysis 61 Acetate Rectal Suppositories 61 Perforomist Inhalation Solution 61 Solid Tumors criteria 61 mg hydrochlorothiazide 61 mg Androxal 61 mg Proellex 61 BENICAR 61 ribavirin RBV 61 adefovir 61 nelfinavir 61 Traficet EN 61 mitoxantrone plus 61 SGPT 61 vicriviroc 61 Teriflunomide 61 ARCALYST ® 61 Pegylated Liposomal Doxorubicin 61 pomalidomide 61 beclomethasone dipropionate 61 rabeprazole 61 serum estradiol 61 COMBIVIR 61 interferon alfa 2a 61 brivaracetam 61 relapsers 61 REYATAZ r 61 icatibant 61 CrCl 61 dosed orally 61 HBeAg positive 61 terazosin 61 tenofovir DF 61 IIIa inhibitor 61 urate lowering 61 platelet inhibitor 61 Panzem R NCD 61 hypoglycemic events 61 #mg dose [001] 61 LB# [003] 61 virologic failure 61 #mg #mg #mg [003] 61 prospective multicenter randomized 61 FUSILEV enhances 61 -#.# ± [002] 61 hA# 61 PD LID 61 pharmacokinetic interactions 61 febrile neutropenia 61 edoxaban 61 QT QTc 61 PEG Intron 61 TNFalpha 61 amoxicillin clavulanate 61 achieved CCyR 61 systemic bioavailability 61 R# #mg BID 61 bolus injection 61 Cimzia TM 61 thalidomide Thalomid 61 PCWP 61 azacitidine 61 controlled multicenter 61 stent binary restenosis 61 levosimendan 61 placebo controlled clinical trials 61 statistically significant improvement 61 #.#/#.# mm Hg [003] 61 lumbar spine bone 61 dose Iluvien 61 #μg [001] 61 EDEMA3 trial 61 anagrelide 61 low dose cytarabine 61 doripenem 61 mg RDEA# 61 nonsignificant difference 61 quetiapine 61 HBeAg 61 dose titration 61 efficacy tolerability 61 virological response 61 VaD 60 protein excretion 60 Pharmacokinetic 60 IFN alfa 60 neutrophil counts 60 macroalbuminuria 60 SIMPADICO 60 HbA1C 60 Xelox 60 CombAT 60 ABC/3TC 60 TNSS 60 nasopharyngitis 60 adenoma recurrence 60 HCV SPRINT 60 % CI #.#-#.# [007] 60 miconazole 60 maximal doses 60 Peginterferon 60 insulin glulisine 60 mapatumumab 60 gefitinib Iressa 60 imiquimod cream 60 GFT# 60 beta interferons 60 nonfatal MI 60 pertuzumab 60 CK # administered 60 FOSRENOL ® 60 Baseline characteristics 60 cisplatin gemcitabine 60 salmeterol HFA MDI 60 liposomal doxorubicin 60 mmol kg 60 daunorubicin 60 VESIcare 60 uM 60 radezolid 60 chloride secretion 60 MADRS 60 standard chemotherapy regimen 60 adalimumab Humira 60 colesevelam 60 Ramipril 60 virologic 60 unfractionated heparin 60 ginkgo extract 60 Darusentan 60 NOXAFIL Oral Suspension 60 recurrent venous thromboembolism 60 GLYX 60 β blocker 60 mCi kg 60 MIRAPEX 60 sitagliptin Januvia 60 LEXIVA 60 antiepileptics 60 lactate dehydrogenase 60 zoledronic acid 60 tanespimycin 60 fluvastatin 60 doxazosin 60 gemcitabine carboplatin 60 docetaxel chemotherapy 60 Refractory Hodgkin Lymphoma 60 cardiovascular calcification 60 pharmacodynamic endpoints 60 nausea somnolence 60 trials RCTs 60 urocortin 2 60 mg administered orally 60 ALT normalization 60 ACE inhibitor ramipril 60 receiving ISENTRESS 60 isoproterenol 60 Betaferon R 60 Mg Uk 60 ADAGIO study 60 plus octreotide LAR 60 multivariable adjusted 60 gemcitabine Gemzar 60 plasma uric acid 60 thrombocytopenic 60 univariate analysis 60 DU #b 60 APPRAISE 60 confidence interval CI 60 mg eq 60 PEGINTRON TM 60 tamoxifen Nolvadex ® 60 ACTEMRA 60 serum ALT 60 eosinophilic asthma 60 metformin hydrochloride 60 Androgel R 60 serum potassium 60 HIV HCV coinfected 60 symptomatic intracranial hemorrhage 60 treatment emergent adverse 60 DMARD 60 BoNTA 60 humanized interleukin 6 60 FOLFIRI alone 60 boosted protease inhibitor 60 detectable HCV RNA 60 ezetimibe simvastatin 60 olmesartan medoxomil 60 WOMAC scores 60 Zemplar Capsules 60 oral allopurinol 60 phonophobia 60 mg subcutaneous 60 Ki# 60 forodesine 60 reactogenicity 60 clobazam 60 K ras mutations 60 plasma kallikrein inhibitor 60 periprocedural 60 receiving INTRON 60 left ventricular diastolic 60 Known hypersensitivity 60 lispro alone 60 hepatic enzyme 60 Median PFS 60 CORDAPTIVE 60 multivariate Cox 60 oral prodrug 60 chills fever headache 60 NYHA functional class 60 diuretic chlorthalidone 60 severe neutropenia 60 systemically administered 60 telmisartan 60 Linagliptin 60 CYT# QbG# 60 radiographic progression 60 mucosal healing 60 cobiprostone 60 SPRYCEL ® 60 Tasigna prolongs 60 oral olanzapine 60 eosinophil count 60 Ophena TM 60 intraobserver 60 mITT population 60 Hb A1C 60 anthracycline taxane 60 WOMAC pain 60 hemoglobin A1c levels 60 Taxus Stent 60 PSA nadir 60 fluorouracil 60 antibody titer 60 statistically significant reduction 60 CTAP# Capsules 60 fluoropyrimidine 60 PREMPRO 60 placebo PBO 60 AGILECT ® 60 incontinence episodes 60 metformin monotherapy 60 neutropenia dehydration dyspnea 60 EQUETRO 60 ALA PDT 60 CDAI score 60 glycosylated hemoglobin levels 60 interobserver agreement 60 statistically significant differences 60 PTHrP 60 serum aminotransferase levels 60 serum phosphate levels 60 efavirenz EFV 60 glatiramer acetate 60 serum IGF 60 FOLFOX6 chemotherapy regimen 60 leuprorelin 60 oral antidiabetes 60 eptifibatide 60 mometasone furoate 60 endothelin receptor 60 Proellex TM 60 motesanib 60 aminotransferase levels 60 detemir 60 florbetaben 60 ACR# [002] 60 Scale PANSS 60 scintigraphic 60 hematologic toxicity 60 statin monotherapy 60 pregabalin 60 HuMax EGFr 60 tertile 60 divalproex sodium 60 pyrimidine nucleoside analog 60 pharmacodynamic parameters 60 trastuzumab Herceptin ® 60 tHcy 60 histologic subtype 60 Capecitabine 60 Mg Usa 60 Pain Intensity 60 renal toxicity 60 A1c levels 60 rosuvastatin Crestor 60 aminotransferases 60 paliperidone palmitate 60 XELOX 60 Xibrom TM 60 FTC TDF 60 subgroup analyzes 60 kilogram mg kg 60 LymphoStat B belimumab 60 Contrave# 60 liposomal formulation 60 otamixaban 60 serum testosterone 60 receptor blocker 60 kappa = 60 mcg Albuferon 60 unfractionated heparin UFH 60 decitabine 60 fenofibric acid 60 Hazard Ratio HR 60 coronary stenosis 60 Aflibercept 60 AZT zidovudine Retrovir 60 Tipranavir 60 ramelteon 60 Telithromycin 60 μg mL 60 darunavir 60 Tolerability 60 MIRCERA 60 naïve HCV 60 REYATAZ r arm 60 metastatic malignant 60 serum triglycerides 60 bronchodilation 60 Pemetrexed 60 mmHg p = 60 beta 1a 60 intima media thickness IMT 60 prednisone prednisolone 60 Dual Opioid 60 erlotinib Tarceva ® 60 antiandrogens 60 tecarfarin 60 tenecteplase